CoChat

Rifaximin pharmacology and clinical implications

Ojetti, Veronica, Lauritano, Ernesto Cristiano, Barbaro, Federico, Migneco, Alessio, Ainora, Maria Elena, Fontana, Luigi, Gabrielli, Maurizio, Gasbarrini, Antonio · 2009 · Expert Opinion on Drug Metabolism & Toxicology
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, with a low gastrointestinal absorption and a good antibacterial activity. The antibacterial action covers Gram-positive and Gram-negative organisms, both aerobes and anaerobes. Its antimicrobial action is based on its property to bind to the beta-subunit of bacterial DNA-dependent RNA polymerase inhibiting, thereby, the bacterial RNA synthesis. Rifaximin contributes to restore gut microflora imbalance, becoming an important therapeutic agent in several organic and functional gastrointestinal diseases such as hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease and colonic diverticular disease. This antibiotic has the advantage of low microbial resistance and few systemic adverse events and is safe in all patient populations, including young children.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/17425250902973695

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 63

Metadata

Authors
Ojetti, V., Lauritano, E. C., Barbaro, F., Migneco, A., Ainora, M. E., Fontana, L., Gabrielli, M., & Gasbarrini, A.
Venue
Expert Opinion on Drug Metabolism & Toxicology
Published
2009-05-15
Volume
5
Issue
6
Pages
675-682
ISSN
  • 1742-5255 (ISSN-L)
  • 1744-7607
OpenAlex
W2036426721
Cited by
63
References
1
FWCI
1.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rifaximin pharmacology and clinical implications. https://app.cochat.ai/papers/10.1517/17425250902973695
The paper
Ojetti, V., Lauritano, E. C., Barbaro, F., Migneco, A., Ainora, M. E., Fontana, L., Gabrielli, M., & Gasbarrini, A. (2009). Rifaximin pharmacology and clinical implications. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425250902973695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.